This work, and that of colleagues Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib (Gleevec) as primary therapy
for chronic myelogenous leukemia (CML), and the discovery that imatinib resistance is caused by BCR - ABL kinase domain mutations.
Not exact matches
Currently no treatment option is available
for five percent of patients suffering from
chronic myelogenous leukemia, since they have developed resistance to conventional medications.
Her research has recently shown that a signaling pathway dubbed «hedgehog» is important not only
for normal development of stem cells but also
for the growth of cancer cells in
chronic myelogenous leukemia.
The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted
for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are
chronic myelomonocytic
leukemia (CMML), juvenile myelomonocytic
leukemia (JMML), and atypical
chronic myelogenous leukemia (CML).
This knowledge laid the foundation
for the targeted cancer treatment revolution inaugurated by imatinib (Gleevec ®), which has made another blood cancer,
chronic myelogenous leukemia, a controllable,
chronic disease
for many patients.
City of Hope researchers may have discovered a more effective treatment
for patients with
chronic myelogenous leukemia (CML) according to a study published today in Nature Medicine.